Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: Enhanced antitumor efficacy of cisplatin in combination with HemoHIM in tumor-bearing mice

Figure 1

The experimental schedule used for assessing the efficacy of HemoHIM in melanoma-bearing mice which were injected with cisplatin. B16F0 melanoma cells (5 × 105/mouse) were inoculated into subcutaneous femoral left region of mice 3 days before an initial injection of cisplatin. Cisplatin was intraperitoneally injected at 4 mg/kg B.W., and HemoHIM was daily given at 100 mg/kg B.W. from day -1 to day 16. On day 17 after initial injection of cisplatin, all mice of each group were experimented, respectively, to evaluate various parameters.

Back to article page